These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18092832)

  • 1. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
    da Cunha EF; Ramalho TC; Reynolds RC
    J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
    da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
    J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
    Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
    Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
    Kumar M; Vijayakrishnan R; Subba Rao G
    Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors.
    Kronenberger T; Ferreira GM; de Souza ADF; da Silva Santos S; Poso A; Ribeiro JA; Tavares MT; Pavan FR; Trossini GHG; Dias MVB; Parise-Filho R
    Bioorg Med Chem; 2020 Aug; 28(15):115600. PubMed ID: 32631571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases.
    Marelius J; Graffner-Nordberg M; Hansson T; Hallberg A; Aqvist J
    J Comput Aided Mol Des; 1998 Mar; 12(2):119-31. PubMed ID: 9690172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of human dihydrofolate reductase as a binary complex with the potent and selective inhibitor 2,4-diamino-6-{2'-O-(3-carboxypropyl)oxydibenz[b,f]-azepin-5-yl}methylpteridine reveals an unusual binding mode.
    Cody V; Pace J; Nowak J
    Acta Crystallogr D Biol Crystallogr; 2011 Oct; 67(Pt 10):875-80. PubMed ID: 21931219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
    El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
    Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.
    Cody V; Galitsky N; Luft JR; Pangborn W; Rosowsky A; Blakley RL
    Biochemistry; 1997 Nov; 36(45):13897-903. PubMed ID: 9374868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
    Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
    Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of the closed form of Mycobacterium tuberculosis dihydrofolate reductase in complex with dihydrofolate and antifolates.
    Ribeiro JA; Chavez-Pacheco SM; de Oliveira GS; Silva CDS; Giudice JHP; Libreros-Zúñiga GA; Dias MVB
    Acta Crystallogr D Struct Biol; 2019 Jul; 75(Pt 7):682-693. PubMed ID: 31282477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
    Cheng YS; Sacchettini JC
    Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
    Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
    J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
    Desai NC; Trivedi AR; Khedkar VM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.
    Suling WJ; Seitz LE; Pathak V; Westbrook L; Barrow EW; Zywno-Van-Ginkel S; Reynolds RC; Piper JR; Barrow WW
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2784-93. PubMed ID: 10991861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
    Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS
    Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.